referring to reuters
GSK shingles vaccine remains effective after four years: study
GSK shingles vaccine remains effective after four years: study
GlaxoSmithKline's experimental vaccine to prevent the intensely painful condition known as shingles remained 90 percent effective in people over age 70 even four years after receiving the injection, according to data published on Wednesday.In clinical trials, GSK's Shingrix has shown greater protection for older recipients than what has been demonstrated by Merck & Co's rival Zostavax vaccine.The drug is one of GSK's biggest new product hopes.
additionally philly
GlaxoSmithKline's shingles vaccine shows positive results in adults 70 and older
GlaxoSmithKline's shingles vaccine shows positive results in adults 70 and older
Airlines offer up to $38.50-an-hour pay to lure new pilotsAirlines offer up to $38.50-an-hour pay to lure new pilots Sep 14Linda Loyd writes about Philadelphia International Airport, the airline industry, and the ports on the Delaware River.GlaxoSmithKline said Wednesday that it plans to file for regulatory approval to commercialize its experimental shingles vaccine by the end of the year, based on positive results from two late-stage studies in older adults.Scientific data about Glaxo's shingles vaccine, Shingrix, was published this week in the New England Journal of Medicine coming out Thursday.
furthermore upi
Experimental shingles vaccine looks effective
Experimental shingles vaccine looks effective
WEDNESDAY, Sept. 14, 2016 -- An experimental vaccine against shingles may offer lasting protection for most older adults who receive it, a new clinical trial found.Shingles is a painful rash that's triggered by a reactivation of the virus that causes chickenpox.About one-third of Americans develop the disease at some point, according to the U.S. Centers for Disease Control and Prevention (CDC).
No comments:
Post a Comment